ClinicalTrials.gg
Not yet recruitingNCT07440992Bio-PreTDAHUpdated Feb 27, 2026

Identification of Early Biomarkers of Pre-school ADHD

An observational study in ADHD, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 3 Years to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
60
Ages
3 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 7 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Assistance Publique - Hôpitaux de Paris.

Started
2026
with 3 others
Observational
5 of 11
4 open now
Registered
9th of 11
by date

Among the 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris, this one is one of 4 that started in 2026, is one of 5 observational ones, and was the 9th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

7 of the 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 3 Years to 5 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

ADHD affects around 5% of children and manifests itself as hyperactivity, attention difficulties and motor control and balance problems. The prevalence of ADHD is particularly high in certain populations, affecting up to 25-30% of children born prematurely and around 20% of children with neurological conditions such as epilepsy. This disorder is officially diagnosed from the age of 6, according to current criteria. However, its clinical manifestations appear much earlier, having a significant impact on all aspects of the child's life, particularly in the most severe forms, which are often unrecognised due to a lack of clinical resources, and therefore without appropriate treatment.

The creation of a platform dedicated to children at risk of ADHD will enable specific clinical expertise to be developed, with the aim of proposing early targeted interventions and positively influencing the development of their trajectory. This platform will also aim to develop new diagnostic methods, based on indirect measures of attentional and executive processes, balance and the development of a risk measurement scale. This development is essential, as the assessment tools currently available lack specificity.

In order to demonstrate the reliability of the innovative diagnostic methods proposed, a comparative pilot study between children from the first clinical cohort (N=30) and a group of healthy children of the same age (N=30) will be carried out. This will enable us to study the discrimination of our tools and make any necessary adjustments. This pilot study also includes a longitudinal re-evaluation, at 12 months, of the children in the ADHD cohort, in order to study changes in these biomarkers over time.

Read the detailed description

ADHD and control patients will be informed of the study at least 1 week before the inclusion visit.

During the inclusion visit, after consent has been obtained from those with parental authority, patients in both groups will be :

  • Review of inclusion and non-inclusion criteria
  • Neuropsychological assessment: WPPSI-IV; K-CPT
  • Self-questionnaires: ADHD-RS preschool version, temperament scale (CBQ)
  • Experimental evaluation: Eye movement recording, vestibular examination, postural recording, VVS test Patients in the ADHD group will be reassessed at 12 months using the same procedure as the inclusion visit.
03

Conditions studied

  • ADHD

Keywords

  • Psychiatry
  • pediatry
  • ADHD
04

Who can participate

Ages eligible
3 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

30 children aged between 3 and 5 years and 11 months, with clinical criteria for ADHD, will be compared with 30 healthy children of the same age.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For ADHD subjects:
  • Children aged between 3.0 and 5 years and 11 months, with clinical criteria for ADHD, according to DSM 5.
  • Children followed in the Child and Adolescent Psychiatry Department of Robert Debré Hospital.
  • Children naïve to pharmacological treatment for ADHD

For control subjects:

  • Children between 3.0 - 5 years and 11 months
  • No known condition or disease affecting development and behavior

Exclusion criteria

Exclusion Criteria:

  • For both groups
  • Intellectual disability according to DSM 5 +- WPPSI IV \< 70
  • Refusal of the child or one of his parents or representatives of parental authority.
  • Patient under AME or not affiliated to a social security scheme
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Patient

    ADHD patients group: Assessement at V0 et V12 months Review of inclusion and non-inclusion criteria * Neuropsychological assessment: WPPSI-IV; K-CPT * Self-questionnaires: ADHD-RS preschool version, temperament scale (CBQ) * Experimental evaluation: Eye movement recording, vestibular examination, postural recording, VVS test

  • Control

    Control subjects group, with no know conditions or desease affecting development and behavior: assessement only at V0 Review of inclusion and non-inclusion criteria * Neuropsychological assessment: WPPSI-IV; K-CPT * Self-questionnaires: ADHD-RS preschool version, temperament scale (CBQ) * Experimental evaluation: Eye movement recording, vestibular examination, postural recording, VVS test

06

What researchers measure

Primary outcomes

  1. Scores obtained in eye tracking tests between the ADHD group and the control group (fixation duration)

    Identification of biomarkers of visual attention by comparing scores obtained in eye-tracking tests between the ADHD group and the control group.

    Time frame: At baseline

  2. Scores obtained in eye tracking tests between the ADHD group and the control group (latencies)

    Identification of biomarkers of visual attention by comparing scores obtained in eye-tracking tests between the ADHD group and the control group

    Time frame: At baseline

  3. Scores obtained in eye tracking tests between the ADHD group and the control group (number of errors)

    Identification of biomarkers of visual attention by comparing scores obtained in eye-tracking tests between the ADHD group and the control group

    Time frame: At baseline

Secondary outcomes

  1. Scores obtained in vestibular tests in both groups and Progression at 12 months in the ADHD group (clinical exam)

    Identifying biomarkers linked to vestibular function in ADHD children compared to controls

    Time frame: At baseline

  2. Scores obtained in Subjective visual vertical test in both groups and Progression at 12 months in the ADHD group

    Evaluate the diagnostic performance of the different biomarkers (visual and vestibular attention) in relation to the usual neuropsychological tests or self-questionnaires

    Time frame: At baseline & at 12 months

  3. WPPSI (Wechsler Preschool and Primary Scale of Intelligence) sub-scores in both groups and Progression at 12 months in the ADHD group

    Evaluate the diagnostic performance of the different biomarkers (visual and vestibular attention) in relation to the usual neuropsychological tests or self-questionnaires

    Time frame: At baseline & at 12 months

  4. K-CPT (Conners Kiddie Continuous Performance) scores in both groups (impulsivity scores) and Progression at 12 months in the ADHD group

    Evaluate the diagnostic performance of the different biomarkers (visual and vestibular attention) in relation to the usual neuropsychological tests or self-questionnaires

    Time frame: At baseline & at 12 months

  5. Parent self-questionnaire scores in both groups and Progression at 12 months in the ADHD group

    Evaluate the diagnostic performance of the different biomarkers (visual and vestibular attention) in relation to the usual neuropsychological tests or self-questionnaires

    Time frame: At baseline & at 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 86 non-industry observational studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 69. This study's planned 12 months is below that.

Counting every sponsor, half of 96 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 27, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07440992
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Ana MOSCOSO, MD
Contact
ana.moscoso@aphp.fr
+33(0)1 40 03 22 95

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion